Jami Rubin, At Goldman Sachs, Bumps Merck Equity Up Two Notches -- To $73...

I still think Goldman (firm wide, given its vast debt underwriting desks) has some inherent conflicts here -- but I do think the move (given the immuno-oncology outcomes data in Chicago last week) makes sense, as to Merck's 12 to 24 month future per share NYSE values.

The link -- and a bit:

. . . .Goldman Analyst Jami Rubin upgrades Merck (NYSE: MRK) from Neutral to Conviction Buy with a price target of $73.00 (from $63.00). . . .

Now you know -- onward, on a stellar day. . . even as more senseless AR-15 automatic rifle mayhem afflicts Antioch, anew. When will it be enough, Mr. Trump? When? But I will resolve to remain focused on all the good that ordinary Americans are doing -- in spite of 45’s dysfunction. . . .

नमस्ते